Гемопоэтический цитокинез: IL, литература
Cozzi PJ, Padrid PA, Takeka J, et al: Sequence and functional characterization of feline interleukin 2. Biochem Biophys Res Commun 194:1038,1993. Describes cloning of feline IL-2 cDNA and synthesis of bioactive recombinant feline IL-2.
Hay CW, Chu Q, Budsberg SC, et al: Synovial fluid interleukin-6, tumor necrosis factor, and nitric oxide values in dogs with osteoarthritis secondary to canine cranial cruciate ligament rupture. Am J Vet Res 58:1027, 1997. Prospective study of inflammatory mediators IL-6, TNF, and nitric oxide in synovial fluid from stifle joints of dogs with cranial cruciate ligament disease that could contribute to cartilage injury.
Helfand SC, Modiano JF, Moore PF, et al: Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma. Blood 86:636,1995. Constitutive expression of IL-2 receptors and aberrant production of IL-2 by canine leukemic cells with dermatotropism suggest an autostimulatory mechanism for this malignancy.
Helfand SC, Modiano JF, Nowell PC: Immunophysiological studies of interleukin-2 and canine lymphocytes. Vet Immunol Immunopathol 33:1,1992. Characterizes bioactivity of hrIL-2 in the dog and investigates IL-2-dependent pathways in canine peripheral blood lymphocytes.
Helfand SC, Soergel SA, Dormer RL, et al: Potential to involve multiple effector cells with human recombinant IL-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model. J Immunother 16:188,1994a. Investigates expression and targeting of gangBosides on canine melanoma by IL-2-activated canine leukocytes directed against melanoma antigens with antiganglioside antibodies.
Helfand SC, Soergel SA, MacWilliams PS, et al: Clinical and immunolog-ical effects of human recombinant interleukin-2 given by repetitive weekly infusion in normal dogs. Cancer Immunol Immunother 39:84,1994b. A relatively well-tolerated regimen of IL-2 in dogs induces dramatic increases in lymphocyte numbers and activation, associated with augmentation of their in vitro antitumor reactivity.
Helfand SC, Soergel SA, Modiano JF, etal: Induction of lymphokine- activated killer (LAK) activity in canine lymphocytes with low-dose human recombinant interleukin-2 in vitro. Cancer Biother 9:237,1994c. Examines the ability of a clinically relevant (low) dose of hrIL-2 to enhance the tumoricidal properties of canine peripheral blood lymphocytes in vitro.
Khanna C, Hasz DE, Klausner JS, et al: Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: Canine studies. Clin Cancer Res 2:721,1996. Novel delivery of hrIL-2 encapsulated in liposomes directly into pulmonary tree by inhalation enhanced tumoricidal activity of canine pulmonary leukocytes in vitro.
Kilbourn RG, Owen-Schaub LB, Cromeens DM, et al: NG-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs. J Appl Physiol 76:1130,1994. Shows that hypotension, the major dose-limiting toxicity of IL-2 in humans, also occurs in dogs. IL-2 doses and is mediated by induction of nitric oxide.
Lemarie SL, Horohov DW: Evaluation of interleukin-2 production and interleukin-2 receptor expression in dogs with generalized demod-icosis. Vet Derm 7:213,1996. Determines lymphocytes from dogs with generalized demodicosis produce less IL-2 and express fewer IL-2 receptors than normal dogs, suggesting a Th1-deficient response.
Moore AS, Theilen GH, Newell AD, et al: Preclinical study of sequential tumor necrosis factor and interleukin 2 in the treatment of spontaneous canine neoplasms. Cancer Res 51:233,1991. Shows objective tumor responses in dogs with oral melanoma and cutaneous mast cell tumors treated with TNFfollowed by IL-2.
Peng J, Friese P, George JN, et al: Alteration of platelet function in dogs mediated by interleukin-6. Blood 83:398,1994. Determines that IL-6 enhanced responsiveness of canine platelets to activating stimuli and increased platelet numbers in normal dogs.
Pinelli E, Killick-Kendrick R, Wagenaar J, et al: Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 62:229,1994. Describes a number of immunologic parameters in dogs with chronic Leishmania infantum infection that exhibited eitherpatterns of progressive disease or apparent resistance.
Rivas AL, Tintle L, Kimball ES, et al: A canine febrile disorder associated with elevated interleukin-6. Clin Immunol Immunopathol 64:36,1992. Describes a multiple immunodeficiency, involving antibody- and cell-mediated responses in Chinese Sharpei dogs.
Shi F, Kurzman ID, MacEwen EG: In vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysaccha- ride in normal dogs. Cancer Biother 10:317, 1995. Measures IL-6 activity induced by muramyl dipeptide and lipopolysaccharide in vitro and by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine in vivo in normal dogs; findings suggest that IL-6 may play an important role in the biologic response observed in canine cancer patients treated with L-MTP-PE.
Trembleau S, Germann T, Gately MK, et al: The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 16:383,1995. Review examines the role of interleukin-12 in the induction of autoimmune diseases and discusses potential immunointervention strategies.
Zeidner NS, Mathiason-Dubard CK, Hoover EA: Reversal of feline leukemia virus infection by adoptive transfer of lectin/interleukin-2-activated lymphocytes, interferon alpha, and zidovudine. J Immunother 14:22,1993. Examines the hypothesis that combination chemoimmunotherapy might induce the clearance of FeLV infection; results suggest that combined treatment that uses IFN-a and adoptive lymphocyte transfer induced the reversal of retroviremia.
